Mesoblast gains on FDA nod for graft-versus-host disease cell therapy

Mesoblast

19/12/2024 10:50

** U.S.-listed shares of Australia-based Mesoblast  MSB.AX 
rise 44.2% to $17.67 premarket  
    ** The U.S. Food and Drug Administration late on Wednesday
approved co's cell therapy for treating graft-versus-host
disease (GVHD)  
    ** The therapy, branded as Ryoncil, is approved to treat
pediatric patients aged two months and older whose GVHD symptoms
have not responded to standard steroid therapy 
    ** GVHD is a complication that might occur after a cell
transplant, where the donated stem cells attack the recipient's
cells, mistaking them for an unfamiliar threat
    ** Up to last close, stock rose ~457% YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))